Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown
Axsome Therapeutics Revenue Highlights
Latest Revenue (Y)
$638.50M
Latest Revenue (Q)
$191.20M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Axsome Therapeutics Revenue by Period
Axsome Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $638.50M | 65.55% |
| 2024-12-31 | $385.69M | 42.53% |
| 2023-12-31 | $270.60M | 440.80% |
| 2022-12-31 | $50.04M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Axsome Therapeutics generated $638.50M in revenue during NA 2025, up 65.55% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Axsome Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $191.20M | -2.45% |
| 2025-12-31 | $196.00M | 14.62% |
| 2025-09-30 | $170.99M | 13.96% |
| 2025-06-30 | $150.04M | 23.53% |
| 2025-03-31 | $121.46M | 2.27% |
| 2024-12-31 | $118.77M | 13.37% |
| 2024-09-30 | $104.76M | 20.19% |
| 2024-06-30 | $87.17M | 16.22% |
| 2024-03-31 | $75.00M | 4.85% |
| 2023-12-31 | $71.53M | 23.77% |
| 2023-09-30 | $57.79M | 23.76% |
| 2023-06-30 | $46.70M | -50.62% |
| 2023-03-31 | $94.58M | 288.06% |
| 2022-12-31 | $24.37M | 44.67% |
| 2022-09-30 | $16.85M | 91.00% |
| 2022-06-30 | $8.82M | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Axsome Therapeutics generated $191.20M in revenue during Q1 2026, up -2.45% compared to the previous quarter, and up 160.99% compared to the same period a year ago.
Axsome Therapeutics Revenue Breakdown
Axsome Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Product | $633.80M | $381.68M | $202.46M |
| License | - | - | $65.73M |
| Royalty | - | - | $2.40M |
Axsome Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $4.07M | $2.07M | $1.08M | $1.10M | $1.03M | $903.00K | $783.00K | $667.00K | $683.00K | $272.00K | - | - |
| Product | $189.40M | $194.69M | $169.78M | $148.96M | $120.36M | $203.84M | $103.74M | $74.10M | $70.75M | $57.13M | $46.02M | $28.57M |
| Milestone Revenue | $500.00K | - | - | - | - | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | $65.73M | $65.73M | - |
Axsome Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (97.64%), Royalty (2.10%), and Milestone Revenue (0.26%).
Axsome Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| UNITED STATES | $628.62M | $378.16M | $197.22M | - |
| Non-US | $5.18M | $4.02M | $65.73M | $900.00K |
Axsome Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (99.18%), and Non-US (0.82%).
Quarterly Revenue by Country
| Country | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $1.30M | $353.00K | $1.21M | $2.51M | $1.10M | $2.09M | $1.03M | $903.00K | - | $65.73M | $600.00K | $1.70M |
| UNITED STATES | $188.87M | $193.58M | $169.18M | $146.45M | $119.41M | $202.08M | $102.81M | $73.27M | $141.44M | $55.78M | - | - |
Axsome Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (99.31%), and Non-US (0.69%).
Axsome Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | $4.27B | $1.07B |
| ARWR | Arrowhead Pharmaceuticals | $829.45M | $73.74M |
| AXSM | Axsome Therapeutics | $638.50M | $191.20M |
| RYTM | Rhythm Pharmaceuticals | $189.76M | $60.11M |
| CYTK | Cytokinetics | $88.04M | $19.36M |
| MRUS | Merus | $36.13M | $12.15M |
| CRSP | CRISPR Therapeutics | $3.51M | $1.46M |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| MTSR | Metsera | - | - |
| ABVX | Abivax | - | - |